olomorasib + pembrolizumab + pemetrexed + platinum chemotherapy

This is a combination regimen used for the treatment of **advanced or metastatic non–small cell lung cancer (NSCLC) with KRAS G12C mutations**. It consists of: - **Olomorasib:** A second-generation, highly selective small molecule inhibitor of GDP-bound KRAS G12C, targeting a driver mutation in NSCLC. - **Pembrolizumab:** A monoclonal antibody immune checkpoint inhibitor, targeting PD-1, used to promote anti-tumor immunity. - **Pemetrexed:** An antimetabolite chemotherapy agent that inhibits folate-dependent enzymes essential for DNA synthesis. - **Platinum chemotherapy (usually cisplatin or carboplatin):** Alkylating agents that induce DNA crosslinking and apoptosis in rapidly dividing cells. The regimen is being evaluated as first-line treatment in patients with unresectable advanced or metastatic NSCLC, especially those with **PD-L1 expression ≥50%**, as part of global phase 3 trials (SUNRAY-01, NCT06119581). Olomorasib and pembrolizumab have received FDA breakthrough therapy designation for this indication[1][4][8].

Other names

olomorasib + pembrolizumab + pemetrexed + platinum chemotherapy